|
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease Clinical research trials and Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease. Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease clinical trial. Test subjects typically obtain the finest healthcare available for their Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
For Condition: HIV Infections,Gastrointestinal Diseases
Status: Completed
Sponsor(s): Astra USA ,
Synopsis: PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy. SECONDARY: To determine frequency of and time to recurrence of gastrointestinal symptoms, response rate of pathological lesions, and incidence of nongastrointestinal CMV disease in this patient population.
Details: Patients receive intravenous foscarnet either as induction only for 4 weeks or as induction for 4 weeks followed by maintenance for 22 weeks. All patients are followed for 26 weeks or until relapse.
Eligibility:
Study Type: Interventional, Treatment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - AIDS. - CMV GI disease. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Non-GI CMV disease. - Ulcerative colitis, inflammatory bowel disease, or other condition that may interfere with study results. - Other GI pathogens. Concurrent Medication: Excluded: - Drugs that may interact with foscarnet. - Systemic acyclovir, ganciclovir, or acyclovir prodrug. - Drugs known to affect renal function. Prior Medication: Excluded: - Prior foscarnet in extremis. - Investigational agents other than 3TC or d4T within 7 days prior to study entry.
Total Enrollment: 145
Location and Contact Information:
Miami Veterans Administration Med Ctr
Miami, Florida, 33125
United States
Dr Douglas Dieterich
New York City, New York, 10016
United States
Univ TX Galveston Med Branch
Galveston, Texas, 77555
United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612
United States
Los Angeles County - USC Med Ctr
Los Angeles, California, 90033
United States
East Bay AIDS Ctr
Berkeley, California, 94705
United States
Ohio State Univ Hosp
Columbus, Ohio, 43210
United States
Comprehensive Care Ctr
Dallas, Texas, 75235
United States
Med College of Virginia
Richmond, Virginia, 232980711
United States
UCSF - San Francisco Gen Hosp
San Francisco, California, 94110
United States
Dept of Veterans Affairs
Northport, New York, 11768
United States
Houston Veterans Administration Med Ctr
Houston, Texas, 77030
United States
UCSD
San Diego, California, 92103
United States
Dr Robert Bresalier / Henry Ford Hosp
Detroit, Michigan, 48202
United States
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois, 60612
United States
Emory Univ School of Medicine
Atlanta, Georgia, 30303
United States
Additional Information:
Study ID Numbers: 020I; 93-FOS-29
Study Start Date:
Record last reviewed: March 1996
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002145
Other Gastrointestinal Diseases Studies:
1. A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2
2. The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients with HIV
3. A Randomized Trial of Tap Water Treatment in the Elderly
4. Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
5. Regulation of human intestinal bile acid transport in health and disease
Related Studies:
Other Gastrointestinal Diseases Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
|
|
|
|
|
|
|
|